| Name | : Mr. MAI | NAS KUMAR MANDAL (53 /M |) | Date : 29/03/2024 | | |
|------------------------------|---------------------|--|---|----------------------------|--|--|
| Address | : 7 J N RA INDIA | AY BAHADUR ROAD,PO/PS-I | BALLY, HOWRAH, HOWRA | H, WEST BENGAL, | | |
| Examined I | by: | | | UHID : AGHL.0001504015 | | |
| Package | : MEDIWHE | EL - FULL BODY ANNUAL PI | LUS WITH TMT MALE HCK AHC No : AMHLAH20 | | | |
| | COMPLA | INTS | Skin | | | |
| For corporate health checkup | | | - Nil Significant | | | |
| No specific com | | | Present medication | ons | | |
| PRESENT KI | | NESS | - UROMAX 0.4 ELTROXIN 25 | | | |
| No history of | | - Diabetes mellitus, Hypertension, Dyslipidemia | Past medical histo | NP17 | | |
| Thyroid disease | e | - hypothyroidism; | Others | - CA URINARY BLADDER | | |
| | | Medication - regular | Others | - CA URINARY BLADDER | | |
| Others | | - Prostatatomegaly on medication | Surgical history | | | |
| - | | medication | Others | - TURBT 2022 | | |
| DRUG | ALLERG | Y | | | | |
| NO KNOWN ALLE | ERGY | :11/03/2023 | T Personal history | | | |
| | | | Marital status | - Married | | |
| | | | Diet | - Non Vegetarian | | |
| Cardiovascula | r svetom | | Alcohol | - does not consume alcohol | | |
| - Nil Significant | - | | Smoking Chews tobacco | - No - No | | |
| U U | | | Physical activity | - Mild | | |
| Respiratory sy | | | | | | |
| - Nil Significant | | | Family history | | | |
| Gastrointestina | al system | | Father | - alive | | |
| - Nil Significant | | | Mother | - alive | | |
| Genitourinary | svstem | | Diabetes | - father | | |
| - Nil Significant | - | | Coronary artery | - none | | |
| · | | | disease | Nene | | |
| Central nervou | - | | Cancer | - None | | |
| - Nil Significant | | | PHYSICAL EXAMINA | TION | | |
| Eyes | | | 🛃 General | | | |
| Vision - normal | with glasse | s; Glasses - yes | | 404 | | |
| ENT | | | Height Weight | - 184 - 85 | | |
| - Nil Significant | | | BMI | - 85 - 25.11 | | |
| Musculoskelet | al svstem | | Pallor | - No | | |
| Spine and joints | - | | Oedema | - no | | |
| - Nil Significant | | | Cardiovascular system | | | |

Date : 29/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH201776

| Heart rate (Per minute) | - 58 |
|-------------------------|----------------|
| Rhythm | - Regular |
| | - B.P. Sitting |
| Systolic(mm of Hg) | - 98 |
| Diastolic(mm of Hg) | - 68 |
| Heart sounds | - S1S2+ |
| | |

Respiratory system

| Breath sounds | |
|---------------|--|
| | |

 Normal vesicular breath sounds



Tenderness

y - No - No

Opthalmology consultation

Opthalmology findings

- PGVA:RE:6/9 LE:6/9 BCVA:RE:N6 LE:N6 OCULAR MOVEMENT:WNL ANT.SEG:WNL ACCPT: SPECTACLE PWR RE:-1.00/-0.75X95*(6/6) LE:+0.75/-1.00X85*(6/6) ADD(BE):+2.50DSPH(N6) ADVICE:*Glass Rx.*Review after 1yr/SOS

Printed By : Benazir Begaum

Date : 29/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

| AHC No | : AMHLAH201776 |
|--------|----------------|
|--------|----------------|

| | | | | | | | | | |
|------------------------------|----------------|----------------------|---------|----------------------|------------------------------------|---------|---------|-------|---------|
| | | - | | Damma | Casts: | Not Fou | Ind | | |
| Test Name | Result | | Level | | Crystals: | Not Fou | Ind | | |
| Hemoglobin RBC COUNT | 13.0 4.37 * | g/dl Millio ul | on/ 🗕 | 13.0-17.0 4.5-5.5 | URINE SUGAR - POS (QUALITATIVE) | T PRAN | DIAL | | |
| Hematocrit - Hct: | 40.2 * | % | • | 41-53 | Test Name | Result | Unit | Level | Range |
| MCV | 92.0 | fl | ٠ | 83-101 | | Nil | | | |
| MCH | 29.8 | pg | • | 27-32 | GLUCOSE(POST PRANDIAL) | | | | |
| МСНС | 32.4 | % | • | 31.5-34.5 | | | | | |
| RDW | 14.0 | % | • | 11.8-14.0 | URINE SUGAR- FAS | • | | | Range |
| WBC Count | 4700 | /cu m | nm 🔍 | 4000-10000 | | Nil | Unit | Levei | Range |
| Platelet Count | 2.53 | lacs/ mm | cu 🔍 | 1.5-4.0 | GLUCOSE(FASTING) | | | | |
| Neutrophils | 58 | % | • | 40-80 | BLOOD GROUPING | AND TYF | PING (/ | ABO A | ND RH) |
| Lymphocytes | 30 | % | • | 20-40 | Test Name | Result | Unit | Level | Range |
| Monocytes | 08 | % | • | 2-10 | ABO Group: | 0 | | | |
| Eosinophils | 04 | % | • | 01-06 | Rh (D) Type: | POSITI | VE | | |
| Basophils | 00 | % | • | 0-0 | LIVER FUNCTION TE | ST (PAC | KAGE | .) | |
| RBC: | Normoc | vtic No | rmochro | omic cells | Test Name | Result | Unit | Level | Range |
| Platelets: | Adequat | - | | | ALT(SGPT) - SERUM | 31 | U/L | • | 0-50 |
| ERYTHROCYTE SEDIMENTATION | 14 | mm/′ hr | 1st 🗨 | 0-15 | ALBUMIN - SERUM | 4.3 | g/dL | • | 3.5-5.1 |
| RATE (ESR) | | | | | ALKALINE PHOSPHATASE - | 88 | U/L | • | 43-115 |
| URINE ROUTINE A | - | | | | SERUM | | | | |
| Test Name | Result | Unit | Level | Range | | | 11/1 | | 0.50 |
| Volume: | 40 | mL | | | AST (SGOT) - SERUM | 23 | U/L | - | 0-50 |
| Colour: | Pale Str | aw | | | | 0.6 | ma/d | | 0212 |

| Adequate |) . | | | ALT(SGPT) - SERUM | 31 | U/L | • | 0-50 |
|--|--|-------|-------|---|-----------------------------|--------------------------------|-------|-----------------------|
| 14 | mm/1s hr | t ● | 0-15 | ALBUMIN - SERUM | 4.3 | g/dL | • | 3.5-5.1 |
| MICROS | | , | | ALKALINE PHOSPHATASE - SERUM | 88 | U/L | • | 43-115 |
| Result | Unit | Level | Range | | | | | |
| 40 | mL | | | AST (SGOT) - SERUM | 23 | U/L | • | 0-50 |
| Pale Stra | w | | | | | | | |
| Clear | | | | BILIRUBIN TOTAL - SERUM | 0.6 | mg/dl | - | 0.3-1.2 |
| 1.015 | | | | | | | | |
| 7.0 | | | | LIPID PROFILE TEST | (PACKA | GE) | | |
| | | | | | | | | |
| 7.0 | | | | Test Name | Result | Unit | Level | Range |
| 7.0 Not Dete | cted | | | Test Name CHOLESTEROL - | Result 148 | Unit mg/dl | - | Range 0-200 |
| | | | | | | | - | |
| Not Deteo | cted | | | CHOLESTEROL - SERUM | 148 | | - | |
| Not Detec | cted cted | | | CHOLESTEROL - | 148 | mg/dl | - • | 0-200 |
| Not Detection | cted cted | | | CHOLESTEROL - SERUM CREATININE - SERUM | 148 I | mg/dl Unit | - • | 0-200 |
| Not Detection Not Detection Not Detection | cted cted cted /hpf | | | CHOLESTEROL - SERUM CREATININE - SERUM Test Name CREATININE - SERUM | 148 Result 0.9 | mg/dl Unit mg/dl | Level | 0-200 Range |
| Not Detect Not Detect Not Detect Not Detect | cted cted cted /hpf al/hpf | | | CHOLESTEROL - SERUM CREATININE - SERUM Test Name | 148 Result 0.9 | mg/dl Unit mg/dl KAGE | Level | 0-200 Range |

Within Normal Range

Borderline High/Low

Out of Range

Appearance

pH:

Albumin:

Glucose

Ketone:

RBC

Pus Cells

Bile Pigments

Epithelial Cells

Specific Gravity

Date : 29/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH201776

| GGTP: GAMMA GLUTAMYL TRANSPEPTIDASE - SERUM | 12 | U/L | • | 0-55 | TOTAL T3: TRI IODOTHYRONINE - SERUM | 1.03 | ng/ml | • | 0.87-1.78 |
|--|---|---|------------|--|--|---|-------------------------------|------------|-------------------------------------|
| GLUCOSE - PLASMA | (FASTI | NG) | | | TOTAL T4: THYROXINE - SERUM | 8.89 | µg/dL | • | 5.48-14.28 |
| Test Name | Result | Unit | Level | Range | | | | | |
| GLUCOSE - PLASMA | 93 | mg/dL | • | 70-99 | LIPID PROFILE TEST | (PACKA | (GE) | | |
| (FASTING) | | | | | Test Name | Result | Unit | Level | Range |
| GLUCOSE - PLASMA | (POST | PRANC |)IAL) | | TRIGLYCERIDES - | 117 | mg/dL | • | 0-150 |
| Test Name | • | Unit | | Range | SERUM | | | | |
| GLUCOSE - PLASMA | 113 | mg/dL | | 70-140 | THYROID PROFILE - I | (T3,T4 / | AND TS | SH) | |
| (POST PRANDIAL) | | Ū | | | Test Name | Result | Unit | Level | Range |
| IBA1C (GLYCOSYLA IAEMOGLOBIN)-WH | OLE BL | | | _ | TSH: THYROID STIMULATING HORMONE - SERUM | 6.8 * | µIU/m | L | 0.38-5.33 |
| Test Name | Result | | Level | | | | | | |
| | 5.9 * | % | • | Nondiadetic : 4 - 5.6 % | URIC ACID - SERUM Test Name | Result | Unit | Loval | Range |
| (GLYCOSYLATED HAEMOGLOBIN)-WHO |) | | | Prediabetics : 5.7 - 6.4% Diabetes : >/= 6.5% | | | | _ | |
| LE BLOOD | | | | | URIC ACID - SERUM | 5.3 | mg/dL | - | 2.6-7.2 |
| | | | | | LIVER FUNCTION TEST (PACKAGE) | | | | |
| | | | | ADA | Test Name | • | | | Range |
| | | | | Theraputic goal : <7% | BILIRUBIN CONJUGATED (DIRECT) - SERUM | 0.1 | mg/dL | • | 0.0-0.2 |
| IPID PROFILE TEST | (PACKA | ۹GE) | | | | | | | |
| Test Name | Result | Unit | Level | Range | PROSTATIC SPECIFIC | ANTIG | EN (PS | SA TO | TAL) - |
| HDL CHOLESTEROL - | 40 | mg/dL | . • | 30-70 | SERUM | | | | _ |
| | | | | | Test Name | Result | | _ | Range |
| | | | | | PROSTATIC SPECIFIC | 1.18 | ng/mL | • | 0.00-6.50 |
| LDL CHOLESTEROL -SERUM | 92 | mg/dL | • | Optimal: <100 | ANTIGEN (PSA TOTAL) - SERUM | | | | |
| SERUM LDL CHOLESTEROL -SERUM | 92 16 | mg/dL mg/dL | | Optimal: <100 0-35 | ANTIGEN (PSA TOTAL) - SERUM | | EN) | | |
| SERUM | | - | | | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N | | • | l evel | Range |
| SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) | 16 | mg/dL | • | | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N Test Name | Result | Unit | _ | Range 7 0-18 0 |
| SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) | 16 ST (PAC | mg/dL | | 0-35 | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N | | • | _ | Range 7.0-18.0 |
| SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) IVER FUNCTION TES Test Name PROTEIN TOTAL - | 16 ST (PAC | mg/dL | | 0-35 | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) | Result 10.4 | Unit mg/dL | • | |
| SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) LIVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM | 16 ST (PAC Result 7.2 | mg/dL CKAGE) Unit g/dL |) Level | 0-35 Range 6.4-8.3 | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA | Result 10.4 ST (PAC | Unit mg/dL |) | |
| SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) LIVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM GLOBULIN: | 16 ST (PAC Result | mg/dL CKAGE) Unit |) Level | 0-35 Range | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES | Result 10.4 ST (PAC | Unit mg/dL |) | 7.0-18.0 |
| SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) IVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM | 16 ST (PAC Result 7.2 | mg/dL CKAGE) Unit g/dL |) Level | 0-35 Range 6.4-8.3 | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO | Result 10.4 ST (PAC Result 1.5 | Unit mg/dL |) | 7.0-18.0 Range |
| SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) IVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM GLOBULIN: (CALCULATED) - | 16 ST (PAC Result 7.2 | mg/dL CKAGE) Unit g/dL |) Level | 0-35 Range 6.4-8.3 | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO BUN/CREATININE RAT | Result 10.4 ST (PAC Result 1.5 TIO | Unit mg/dL KAGE Unit |) Level | 7.0-18.0 Range 1.0-2.0 |
| SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) LIVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM GLOBULIN: (CALCULATED) - | 16 ST (PAC Result 7.2 2.9 | mg/dL CKAGE) Unit g/dL g/dL |) Level | 0-35 Range 6.4-8.3 | ANTIGEN (PSA TOTAL) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO | Result 10.4 ST (PAC Result 1.5 TIO | Unit mg/dL KAGE Unit |) Level | 7.0-18.0 Range |

UHID : AGHL.0001504015

Date : 29/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH201776

BUN/CREATININE 11.5 RATIO

ECG

SINUS BRADYCARDIA. POOR R WAVE PROGRESSION.

TREADMILL TEST / STRESS TEST

STRESS TEST IS NEGATIVE FOR PROVOCABLE MYOCARDIAL ISCHAEMIA.

ULTRASOUND SCREENING WHOLE ABDOMEN

* Simple cyst in liver.

* Mild prostatomegaly.

[NOTE: At times pelvic structures are not well visualized due to inadequate patient preparation / excess bowel gas shadow. However suggested clinical correlation and other investigations if clinically indicated.

X-RAY CHEST PA

* Chest skiagram does not reveal any significant abnormality.







Out of Range

Date : 29/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH201776

Printed By :

AHC Physician / Consultant Internal Medicine

Note :- The Health Check-up examinations and routine investigations have certain limitations and may not be able to detect all the diseases. Any new or persisting symptoms should be brought to the attention of the Consulting Physician. Additional tests, consultations and follow up may be required in some cases.

Page 7 of 7

Name : Mr. MANAS KUMAR MANDAL (53 /M)

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No ; AMHLAH201776

: 29/03/2024

Date

| | AICVD RISK SCORE REPORT | |
|--------------------|-------------------------|------------------|
| RISK STATUS | YOUR SCORE | ACCEPTABLE SCORE |

| Low Risk | 6 | | 7 |
|----------|---|---|---|
| | | - | |

UHID : AGHL.0001504015

Your cardiovascular disease risk in the next 10 years is within the Normal limits for your age and gender

The AICVD risk score developed by Apollo Hospitals is a novel artificial intelligence based risk scoring system that predicts your risk of having Coronary Artery Disease (CAD) related events in the next ten years. This scoring system uses Indian data and has been validated by multiple national and international institutions. This risk score is more than 92% accurate and has been compiled based on your physical parameters, heart health attributes, lifestyle and medical history. **Note:** The risk category is determined through the ratio between guest score and acceptable score at multiple decimal points. The outputs are shown in whole numbers.

Based on your AICVD risk score you are advised the following:

- Follow the guidance and education on lifestyle and dietary management provided through the ProHealth program. Maintain a healthy BMI (<25). Avoid tobacco in any form and if you are a smoker, stop smoking.
- Continue with **medications** for high blood pressure, diabetes, or dyslipidemia, if advised by your physician. Maintain HbA1c <7% (<53mmol/mol), blood pressure <140/90mmHg.
- Follow your physician's advice regarding follow up tests, consults and annual health assessment

DISCLAIMER

- 1. This is not a diagnostic tool and it does not guarantee accuracy of the result and cannot be acted upon independently.
- 2. This risk score and clinical algorithm is a general guideline for physicians. Any additional laboratory investigations, diagnostic imaging, treatment or patient education related to lifestyle management is under the physician 's or cardiologist's discretion.
- 3. To ensure the information in the report is up to date, accurate and correct, doctor shall be consulted for interpretation of the report.
- 4. Apollo Hospitals and its staff does not offer any assurance on the information made available or be liable for any loss or damage as the said report is based on the AICVD risk score without any intervention from their side .
- 5. By usage of the AICVD risk score, it is deemed that the beneficiary of this service has agreed to get the same done at his own risk and further agrees with this disclaimer without any limitation or any clauses or sub-clauses.

The Clinical AI Models and APIs used at Apollo Hospitals are certified by ISO 13485 : 2016 vide certificate no. MD 763515